event,time
30 years old ,0
    male ,0
    admitted to the hospital ,0
    second dose of mRNA SARS-CoV-2 vaccine ,-936
    fever ,-936
    pleuritic chest pain ,-936
    symptom reduction ,-912
    presyncope ,-240
    hospital admission ,-240
    diagnosis of acute pericarditis ,-240
    cardiac tamponade ,-240
    pericardiocentesis ,-240
    non-steroid anti-inflammatory drugs ,-240
    colchicine ,-240
    relapse of pleuritic chest pain ,-192
    elevated inflammatory markers ,-192
    moderate pericardial effusion ,-192
    admitted to Cardiology ward ,-192
    admitted to cardiac intensive care unit ,-168
    worsening pericardial effusion ,-168
    mild signs of impaired ventricular filling ,-168
    CRP 306 mg/L ,-168
    anakinra started 100 mg twice daily ,-168
    anakinra 100 mg daily ,-168
    no chest pain ,-144
    CRP 287 mg/L ,-144
    no chest pain ,-120
    CRP 179 mg/L ,-120
    complete reabsorption of pericardial effusion ,-96
    CRP 104 mg/L ,-96
    CRP 34 mg/L ,-48
    discharge ,0
    asymptomatic ,0
    good clinical conditions ,0
    large circumferential pericardial effusion ,-168
    diffuse ST elevation ,-168
    PR depression ,-168
    increased heart rate ,-168
    muffled heart sounds ,-168
    jugular vein distension ,-168
    low blood pressure ,-168
    positive anti-spike SARS-CoV-2 IgGs and IgMs ,-168
    negative Epsteinâ€“Barr virus serology and genoma ,-168
    negative Echovirus ,-168
    negative Coxsackevirus ,-168
    negative Adenovirus ,-168
    negative Cytomegalovirus serology ,-168
    negative Quantiferon ,-168
    negative autoimmunity tests ,-168
    negative high-sensitivity Troponin I ,-168
    normal biventricular global and regional function ,-168
    right ventricular diastolic collapse ,-168
    transmitral E wave peak velocity respiratory variation ,-168
    distended inferior vena cava ,-168
    emergency pericardiocentesis ,-240
    ibuprofen 600 mg t.i.d. ,-240
    colchicine 0.5 mg b.i.d. ,-240
    symptom remission ,-240
    downward trend of inflammatory markers ,-240
    negative pericardial fluid analysis ,-240
    ibuprofen tapering ,-192
    disease flare ,-192
    fever ,-192
    pleuritic chest pain ,-192
    increased inflammatory markers ,-192
    CRP 306 mg/L ,-192
    neutrophil leucocytosis ,-192
    ECG signs of acute pericarditis ,-192
    sinus tachycardia ,-192
    large pericardial effusion up to 25 mm ,-192
    incipient signs of impaired ventricular filling ,-192
    readmission to CICU ,-192
    defer pericardiocentesis ,-168
    start anakinra subcutaneously ,-168
    complete resolution of symptoms ,-168
    afebrile ,-168
    asymptomatic ,-168
    normal heart rate ,-144
    complete reabsorption of pericardial effusion ,-96
    abrupt reduction of inflammatory markers ,-72
    discharge on anakinra ,0
    discharge on ibuprofen ,0
    discharge on colchicine ,0
    discharge on proton pump inhibitor ,0
    asymptomatic at follow-up ,24
